News

BREAKING NEWS: The FDA has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease. Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research noted, “Today’s approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non surgical treatment option.” Read more from the FDA regarding research results, adverse reactions, and the FDA's review process.

On Friday, Dec. 13th, the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee met in Silver Spring, MD to discuss teprotumumab, a potential treatment for active thyroid eye disease.

Wishing everyone a beautiful Holiday season and a healthy, happy New Year!

Did you know that your regular online holiday shopping can help the GDATF fund its patient education and support programs?  By purchasing through one of the following channels, online retailers will donate a portion of proceeds to the Graves’ Disease & Thyroid Foundation - at no cost to you!

Amazon Smile Program
iGive
eBay

We're headed to the American Thyroid Association's 89th Annual Meeting in Chicago, IL, which will include a public patient forum on Saturday, November 2nd. This event is hosted by the American Thyroid Association (ATA) Alliance for Patient Education, and will be a great opportunity for patients to interact with advocates and physicians in an informal setting. Click here for details and registration!